Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-12

Whoops are we supposed to know this yet??
Purchase order received already ......

“A significant number of companies have come to a similar conclusion: only PharmAla Biotech can be trusted to ensure a safe, predictable and regulatory-compliant drug supply for patients in the nascent australian medical Psychedelics market,” said Nick Kadysh, PharmAla’s CEO. “We’re thrilled to be able to supply patients through the network of clinics being set up by Incannex, and believe that this is the start of a wonderful relationship.”

Article content

Incannex is a clinical stage pharmaceutical development company that is developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleepapnea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications.

PharmAla is the first publicly-traded company to manufacture GMP MDMA, and the first company to make available to researchers two GMP Psychedelic APIs. Incannex intends to take possession of their order as soon as permitted by regulatory timelines.

Click to read further


https://pharmala.ca/team

Joel's got the order in already it seems!!!

Good luck all, fundamentals are gaining momentum??